tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Johnson & Johnson Reports Strong Q3 2025 Financial Results

Story Highlights
Johnson & Johnson Reports Strong Q3 2025 Financial Results

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Johnson & Johnson ( (JNJ) ) has shared an update.

On October 14, 2025, Johnson & Johnson announced its third-quarter 2025 financial results, reporting a 6.8% increase in sales to $24 billion and a significant rise in net earnings by 91.2%. The company also raised its full-year sales outlook to $93.7 billion, driven by strong performance in its Innovative Medicine and MedTech segments. Key developments included approvals for new treatments and significant progress in its product pipeline, indicating a strategic focus on innovation and growth in priority areas. The announcement highlights the company’s robust financial health and its strategic initiatives aimed at maintaining its leadership position in the healthcare sector.

The most recent analyst rating on (JNJ) stock is a Hold with a $178.00 price target. To see the full list of analyst forecasts on Johnson & Johnson stock, see the JNJ Stock Forecast page.

Spark’s Take on JNJ Stock

According to Spark, TipRanks’ AI Analyst, JNJ is a Outperform.

Johnson & Johnson’s strong financial performance and positive earnings call are the primary drivers of its high score. The company’s robust profitability, strategic growth in key segments, and raised guidance highlight its strong market position. Technical analysis supports a positive trend, while valuation remains reasonable. Overall, J&J is well-positioned for continued success, with some caution advised due to near-term technical indicators.

To see Spark’s full report on JNJ stock, click here.

More about Johnson & Johnson

Johnson & Johnson is a prominent player in the healthcare industry, focusing on pharmaceuticals, medical devices, and consumer health products. The company is committed to innovation and growth in areas such as Oncology, Immunology, Neuroscience, Cardiovascular, Surgery, and Vision.

Average Trading Volume: 8,662,166

Technical Sentiment Signal: Buy

Current Market Cap: $459.8B

See more data about JNJ stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1